reports
- Jacob Mekhael
EHA abstracts Autolus, Galapagos, MaaT
The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
MaaT Pharma 1Q25 reiterates pipeline timelines, cash runway into Octob...
MaaT reported 1Q25 results with revenues of € 1.1m (1Q24 € 0.8m), and a cash position of € 24.4m (YE24: € 20.2m), which provides a cash runway into October 2025. Pipeline timelines were reiterated and we look forward to phase 2 data for MaaT013 in combination with immune checkpoint inhibitors in metastatic melanoma in 2H25, and hope to learn more about the company's progress with respect to partnering discussions for MaaT013 in aGvHD in Europe as we approach MAA submission in June 2025. We reite...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Jacob Mekhael
MaaT Pharma FIRST LOOK: MaaT033 slows disease progression in phase 1 A...
MaaT reported additional results from the exploratory single arm phase 1b trial of MaaT033 in ALS, and we view the slower disease progression observed with MaaT033 as encouraging, though we also note the small patient numbers and single arm nature of the trial. ALS is a difficult condition, where many drugs have failed to show slowing of disease progression. As such, MaaT033's early results are promising, and the company is seeking partners focussed on ALS to progress this program. We reiterate ...
WINFARM : Modalités de mise à disposition du Rapport Financier Annuel ...
WINFARM : Modalités de mise à disposition du Rapport Financier Annuel 2024. COMMUNIQUE DE PRESSE Loudéac, le 30 avril 2025 MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2024 WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce que son rapport financier annuel 2024 a été déposé auprès de l’Autorité des Marchés Financiers (AMF), le 30 avril 2025. Ce document est disponible sur le site de la Société à l’adresse -group.com et sur le site de l’AMF (-france.org). Il est également tenu à disposition au siège...
WINFARM : Ongoing sales momentum in Q1 2025 with +7.9% growth.
WINFARM : Ongoing sales momentum in Q1 2025 with +7.9% growth. PRESS RELEASE Loudéac, April 29, 2025 Ongoing sales momentum in Q1 2025 with +7.9% growth 2025 Outlook: maintained strong sales momentum and expected improvement in results WINFARM (ISIN: FR0014000P11 – Ticker: ALWF), the leading French player in the supply of consulting, services and distance-selling of products and solutions for the agricultural and livestock industry, is today releasing its revenue figures for the first quarter of 2025. In millions of euros, unauditedQ1 2024Q1 2025ChangeFarming Supplies29.931.5+5.3%Fa...
WINFARM : Poursuite de la dynamique commerciale au 1 er trimestre 2025...
WINFARM : Poursuite de la dynamique commerciale au 1 er trimestre 2025 avec une croissance de +7,9%. COMMUNIQUE DE PRESSE Loudéac, 29 avril 2025 Poursuite de la dynamique commerciale au 1er trimestre 2025 avec une croissance de +7,9% Perspectives 2025 : Maintien d’une forte impulsion commerciale et amélioration attendue des résultats WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), 1er groupe français proposant un ensemble de prestations de conseil, de service, et de vente à distance de produits et de solutions au monde agricole et à l’élevage, annonce ce jour la publication du chi...
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Wim Hoste
- Jacob Mekhael
MaaT Pharma MaaT034 preclinical data at AACR shows potential in solid ...
MaaT presented new preclinical data for MaaT034 (donor-independent co-cultured microbiome therapy) at the American Association for Cancer Research (AACR) conference, being held 25-30 April in Chicago. The results show the potential for microbiome therapies to improve responses in solid tumours when combined with immune checkpoint inhibitors. Results from a phase 2 investigator-initiated placebo-controlled trial of MaaT013 (microbiome therapy, enema formulation) in combination with checkpoint inh...
WINFARM : Implantation d'Alphatech à Singapour pour répondre à la fort...
WINFARM : Implantation d'Alphatech à Singapour pour répondre à la forte hausse de la demande sur la zone APAC. COMMUNIQUE DE PRESSE Loudéac, 15 avril 2025 IMPLANTATION D’ALPHATECH A SINGAPOUR POUR REPONDRE A LA FORTE HAUSSE DE LA DEMANDE SUR LA ZONE APAC WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce l’ouverture de sa filiale Alphatech APAC à Singapour. Cette implantation, va permettre à la Société de mieux répondre à l’explosion de la demande sur cette zone stratégique à très fort potentiel. Avec cette nouv...
- Jacob Mekhael
MaaT Pharma Positive DSMB safety analysis for MaaT033 phase 2 in allo-...
MaaT announced the positive outcome of a key DSMB safety interim analysis for the phase 2b trial (PHOEBUS), which compares the efficacy and safety of MaaT033 (microbiome therapy, oral capsule) to placebo in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT). We are encouraged by the DSMB outcome, particularly in the context that allo-HSCT is a high risk patient population, and see this as supportive of MaaT033´s good safety profile. We note that MaaT033 is next...
- Jacob Mekhael
MaaT Pharma To present preclinical data on MaaT034 at AACR
MaaT will present new non-clinical data on MaaT034 (donor independent microbiome therapy) at the American Association for Cancer Research (AACR) conference, taking place on 25-30 April. The results demonstrate MaaT034's potential as a combination therapy to improve responses to checkpoint inhibitors in solid tumours. Being co-cultured means MaaT034 is donor-independent, which offers the scale required for the larger solid tumour market. Initial data from the phase 2 placebo-controlled trial of l...
- Guy Sips
- Jacob Mekhael
- Thomas Vranken
- Wim Hoste
WINFARM : 2024 full-year results and 2025 outlook.
WINFARM : 2024 full-year results and 2025 outlook. PRESS RELEASE Loudéac, 31 March 2025 2024 FULL-YEAR RESULTS Significant improvement in H2 2024 on revenue and EBITDA, in line with targets Solid annual gross margin and positive operating profitability in 2024despite a difficult environment 2025 OUTLOOK Build on H2 2024 momentum to pursue revenue growth Rigorous financial discipline to improve EBITDA Continue reduction of Group debt WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the number one French distance seller for the farming industry, today release its consolidated 2024 ful...
WINFARM : Résultats annuels 2024 et perspectives 2025.
WINFARM : Résultats annuels 2024 et perspectives 2025. COMMUNIQUE DE PRESSE Loudéac, 31 mars 2025 RESULTATS ANNUELS 2024 Deuxième semestre 2024 en nette amélioration en termes de chiffre d’affaires et d’EBITDA conformément aux objectifs fixés Bonne tenue de la marge brute annuelle et rentabilité opérationnelle positive en 2024malgré un contexte difficile PERSPECTIVES 2025 Capitaliser sur la dynamique du 2ème semestre pour poursuivre une croissance du chiffre d’affaires Discipline financière stricte favorisant l’amélioration de l’EBITDA Poursuite du désendettement du Groupe WINFA...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
MaaT Pharma FIRST LOOK: FY24 results extend runway with € 13m private ...
MaaT reported FY24 results with the key item being the private placement of € 13m supported by existing shareholders. This extends the company's runway into October 2025 (previously into 2Q25) and provides sufficient funding to reach a number of milestones including MAA submission for MaaT013 to the EMA (June 2025), and enables the company to make progress with its regulatory interactions with the FDA to clarify the route to market in the US. On the pipeline front, we continue to look forward to...
- Jacob Mekhael
MaaT Pharma FIRST LOOK: Positive DSMB review for lead product MaaT013 ...
MaaT announced that the independent data safety monitoring board (DSMB) completed its final safety assessment of the pivotal phase 3 (ARES) trial of MaaT013 in 3L aGvHD, which was in line with previous evaluations confirming the favourable benefit/risk ratio of the product. As a reminder, MaaT013 met its primary endpoint in the phase 3 (ARES) trial, and results presented in January 2025 demonstrated a 28 day GI-ORR of 62%, which came in above expectations. Looking ahead, we look forward to the r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.